MarketInOut Stock Screener Log In | Sign Up

Hyloris Pharmaceuticals S.A.

BRU • Healthcare • Biotechnology • Quote as of 10/30/2026
Hyloris Pharmaceuticals S.A. stock price and volume chart

Company Profile

IndustryBiotechnology
SectorHealthcare
ExchangeBRU
Market Capitalization102.2 mln
Float12.15 mln
Earnings Date09/24/2026

Piotroski F-Score

1 / 9
Very weak

Beneish M-Score

-2.12
Caution advised

1-Year Forecast

11.23
Transformational upside

Relative Strength

12 / 100
Significantly lagging

Debt / Equity

0.07
Debt-free

Pre-Tax Margin

-55%
Severely loss-making

Business Description

Hyloris Pharmaceuticals is a Belgian drug development company focused on creating improved versions of existing medicines to fill gaps in patient care. Founded in 2012 and based in Liège, the company has built a broad portfolio spanning pain management, heart conditions, infections, and several other therapeutic areas. Hyloris works with a number of partner organizations to bring its products to market and currently has multiple treatments either available or in development.

Key Fundamentals

EPS-0.17
ROE-16.73
RPS0.35
ROIC-42.04
ROA-13.41
EBITDA, mln-3.66
EV / EBITDA-27.63
EV / EBIT-23.50
Revenue, mln8.89
EV / Revenue12.75

Quote Details

Last 3.83
Change -0.03 (-0.78%)
Open 3.72
Volume 2,583
Turnover 9,892.89
Average Volume 8,578.19

Financial Ratios

Pre-Tax Profit Margin-55
Leverage Ratio1.19
Current Ratio4.82
Price / Book4.99
Price / Tangible Book6.64
Debt / Equity0.07
Price / Sales13.99

Financial Strength

Altman Z-Score6.68
Piotroski F-Score 1 / 9
Beneish M-Score-2.12
1-Year Target Price11.23

Price Performance & Relative Strength

Period Price Performance Relative Strength
1 Week -2.79% 16 / 100   
1 Month -9.88% 19 / 100   
2 Months -18.51% 18 / 100   
6 Months -27.19% 17 / 100   
1 Year -32.57% 17 / 100   



Disclaimer - Privacy Policy - Terms of Service - Cookies - FAQ - Affiliates - Blog